Drug Profile


Alternative Names: RWJ 21757

Latest Information Update: 08 Jun 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Developer Johnson & Johnson; Nonindustrial source
  • Class Antineoplastics; Purine nucleosides; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Endometriosis
  • Discontinued Cancer

Most Recent Events

  • 08 Jun 2001 No-Development-Reported for Endometriosis in USA (Unknown route)
  • 18 Jan 1999 A preclinical study has been added to the Women's health pharmacodynamics section
  • 18 Sep 1998 Preclinical development for Endometriosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top